# Lyvgen Biopharma

> Lyvgen Biopharma is a Shanghai-based clinical-stage immuno-oncology company founded in 2016 by veteran oncology scientist Dr. Jieyi Wang. It builds agonist antibodies - drugs that switch the immune system on rather than release its brakes - using a proprietary xLinkAb platform designed to concentrate immune activation inside tumors while limiting toxicity elsewhere. Its lead program, the CD137/4-1BB agonist antibody LVGN6051 (exlinkibart), is in Phase Ib/II trials in the US and China, including combinations with Merck's Keytruda, alongside a CD40 agonist (LVGN7409), a PD-1 blocker (LVGN3616), and bispecific candidates. Backed by IDG Capital and others through a Series C, Lyvgen runs R&D in Shanghai, a CMC/manufacturing center in Suzhou, and clinical and business development teams spanning China and the US.

- **Founded:** 2016
- **Headquarters:** Shanghai, China
- **Founders:** Jieyi Wang (Founder, Chairman & CEO)
- **Team size:** ~17-50 employees (clinical-stage biotech)
- **Products:** xLinkAb platform, LVGN6051 (exlinkibart), LVGN7409, LVGN3616, LVGN1673
- **Notable:** Advanced a second-generation 4-1BB (CD137) agonist, LVGN6051, into Phase Ib/II - a target class that has stalled many prior programs., Reached a recommended Phase 2 dose (4 mg/kg Q3W) for LVGN6051 with an acceptable safety profile and durable objective responses., Selected for multiple ASCO presentations, including two LVGN6051 studies at ASCO 2024 and CD137 data at ASCO 2021.

## Products & services

- **xLinkAb platform** — Proprietary antibody engineering platform that generates agonistic monoclonal and multispecific antibodies with tumor-localized immunostimulatory activity, integrating multiple functions into single candidates.
- **LVGN6051 (exlinkibart)** — Second-generation CD137/4-1BB agonist monoclonal antibody; lead program in Phase Ib/II as monotherapy and in combination with Keytruda (pembrolizumab) in advanced malignancies.
- **LVGN7409** — CD40 agonist monoclonal antibody in clinical development, evaluated in combination regimens for solid tumors.
- **LVGN3616** — Anti-PD-1 blocking antibody used across combination studies.
- **LVGN1673** — Bispecific antibody blocking PD-L1 while trapping TGF-beta 1/2/3.

## Achievements

- Advanced a second-generation 4-1BB (CD137) agonist, LVGN6051, into Phase Ib/II - a target class that has stalled many prior programs.
- Reached a recommended Phase 2 dose (4 mg/kg Q3W) for LVGN6051 with an acceptable safety profile and durable objective responses.
- Selected for multiple ASCO presentations, including two LVGN6051 studies at ASCO 2024 and CD137 data at ASCO 2021.
- Completed Series C financing led by IDG Capital.
- Built a ~2,000 square meter CMC/manufacturing center for therapeutic antibodies in BioBAY, Suzhou.
- Established a genuinely cross-Pacific operation with R&D in Shanghai, manufacturing in Suzhou, and clinical/BD teams in China and the US.

## Latest updates

- **2024-06** — Two LVGN6051 (exlinkibart) clinical studies selected for poster presentation at ASCO 2024, including Phase Ib dose-expansion data in resistant NSCLC, melanoma, and GI malignancy.
- **2024-05** — LVGN6051 reached recommended Phase 2 dose with durable responses in combination with pembrolizumab, including in immune-cold and immunotherapy-relapsed tumors.
- **2021-02** — Completed Series C financing led by IDG Capital with participation from Shanghai FTZ Fund, Suzhou Longmen Venture Capital, and CHENGWEI Capital.
- **2021-06** — Presented CD137/4-1BB agonist LVGN6051 clinical trial data at the 2021 ASCO Annual Meeting.

## Links

- Website: https://www.lyvgen.com
- LinkedIn: http://www.linkedin.com/company/lyvgen-biopharma

---

Profile page: https://yespress.io/lyvgen-biopharma
Published by YesPress — https://yespress.io
Last updated: 2026-07-11